Document is current
Any future updates will be listed below
-
Authors
Glaviano, Antonino
Weisberg, Ellen
Lam, Hiu Y.
Tan, Donavan J. J.
Innes, Andrew J.
Ge, Yubin https://orcid.org/0000-0002-8748-716X
Lai, Catherine E.
Stock, Wendy
Glytsou, Christina https://orcid.org/0000-0002-6260-338X
Smit, Linda
Yoshida, Tatsushi https://orcid.org/0000-0002-0634-5160
Zhang, Tian Y.
Kennedy, Vanessa E.
Smith, B. Douglas
Mercher, Thomas
de Botton, Stéphane
Diana, Patrizia
Konopleva, Marina https://orcid.org/0000-0002-9347-2212
Mauro, Michael J.
Griffin, James D.
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Kumar, Alan P. https://orcid.org/0000-0002-3754-5712
- License Information
-
More Information
Article History
Accepted: 30 July 2025
First Online: 1 September 2025
Competing interests
: B.D.S. is a consultant and adviser of Servier. M.K. is a consultant of AbbVie, Adaptive, AmMax, Curis, Janssen, Kyowa Kirin, Menarini/Stemline Therapeutics, Novartis, Sanofi Aventis, Servier and Vincerx and is an adviser of AbbVie, Auxenion GmbH, Dark Blue Therapeutics, Legend, MEI Pharma, Menarini/Stemline Therapeutics, Novartis and Syndax and receives research funding from AbbVie, Janssen and Klondike Biopharma. C.D.D. is a consultant and/or adviser of Abbvie, Astellas, AstraZeneca, BMS, Daiichi Sankyo, GenMab, GSK, Rigel, Ryvu, Schrodinger, Servier and Solu Therapeutics and has received research funding from Abbvie, Astex, Beigene, BMS, Jazz, ImmuneOnc, Remix, Servier, Schrodinger and Systimmune. A.P.K. serves on the advisory board for AUM Biosciences. The other authors declare no competing interests.
